Natalizumab
- PDF / 170,032 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 69 Downloads / 130 Views
1
S
Progressive multifocal leukoencephalopathy secondary to JC virus infection: 2 case reports In a retrospective study of 142 patients with progressive multifocal leukoencephalopathy (PML) reported to the German Federal Institute for Vaccines and Biomedicines (PaulEhrlich-Institute) until July 2017, two patients [ages and sexes not stated] were described, who developed PML secondary to JC virus infection during treatment with natalizumab for relapsing-remitting multiple sclerosis in Germany. The patients, who had relapsing-remitting multiple sclerosis, received natalizumab infusions [Tysabri; dosage not stated]. Subsequently, both the patients developed PML secondary to JC virus infection [durations of treatments to reactions onsets not stated]. In one patient, brain biopsy, MRI findings and evidence of intrathecal anti-JC polyomavirus antibody synthesis confirmed definite PML (level 1), while in an another patient, MRI findings, clinical symptoms and evidence for intrathecal anti-JC polyomavirus antibody synthesis confirmed possible PML (level 3). In both the cases, the diagnosis of PML was delayed by about 16 weeks [outcomes not stated]. Author comment: "To evaluate characteristics relevant to diagnosis of JC polyomavirus-associated progressive multifocal leukoencephalopathy (PML), and PML risk stratification in a large national cohort of patients with multiple sclerosis during therapy with natalizumab." "The most relevant risk associated with natalizumab therapy is progressive multifocal leukoencephalopathy (PML), a devastating brain disorder caused by JC polyomavirus (JCPyV)." Blankenbach K, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in Germany. Neurology 92: E2232-E2239, No. 19, 7 May 2019. Available from: URL: http://doi.org/10.1212/WNL.0000000000007451 803437089 Germany
0114-9954/19/1781-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved
Reactions 30 Nov 2019 No. 1781
Data Loading...
